These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25096867)

  • 21. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA; Ford L; McClintock C; Peacock M
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
    Sousa T; Bompadre V; White KK
    J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
    Malmgren B; Aström E; Söderhäll S
    J Oral Pathol Med; 2008 Apr; 37(4):196-200. PubMed ID: 18321345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.
    Palomo T; Andrade MC; Peters BS; Reis FA; Carvalhaes JT; Glorieux FH; Rauch F; Lazaretti-Castro M
    Calcif Tissue Int; 2016 Jan; 98(1):42-8. PubMed ID: 26387692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
    Aström E; Magnusson P; Eksborg S; Söderhäll S
    Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients.
    Heino TJ; Aström E; Laurencikas E; Sävendahl L; Söderhäll S
    Horm Res Paediatr; 2011; 75(5):354-61. PubMed ID: 21304249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteogenesis Imperfecta: update on presentation and management.
    Cheung MS; Glorieux FH
    Rev Endocr Metab Disord; 2008 Jun; 9(2):153-60. PubMed ID: 18404382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta.
    Lin HY; Lin SP; Chuang CK; Chen MR; Chang CY
    Pediatr Neonatol; 2008 Oct; 49(5):161-5. PubMed ID: 19133566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
    Choi JH; Shin YL; Yoo HW
    J Korean Med Sci; 2007 Apr; 22(2):209-12. PubMed ID: 17449925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.
    Rauch F; Travers R; Glorieux FH
    J Clin Endocrinol Metab; 2006 Feb; 91(2):511-6. PubMed ID: 16291701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
    Land C; Rauch F; Montpetit K; Ruck-Gibis J; Glorieux FH
    J Pediatr; 2006 Apr; 148(4):456-60. PubMed ID: 16647404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biphosphonates and osteogenesis imperfecta in children].
    Gandon-Laloum S
    Arch Pediatr; 2009 Jul; 16(7):1085-9. PubMed ID: 19423303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
    Bajpai A; Kabra M; Gupta N; Sharda S; Ghosh M
    J Pediatr Orthop; 2007 Mar; 27(2):225-7. PubMed ID: 17314651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw.
    Maines E; Monti E; Doro F; Morandi G; Cavarzere P; Antoniazzi F
    J Bone Miner Metab; 2012 Jul; 30(4):434-8. PubMed ID: 22065238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pamidronate treatment for osteogenesis imperfecta in black South Africans.
    Henderson BD; Isaac N; Mabele O; Khiba S; Nkayi A; Mokoena T
    S Afr Med J; 2016 May; 106(6 Suppl 1):S47-9. PubMed ID: 27245525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
    Rauch F; Plotkin H; Zeitlin L; Glorieux FH
    J Bone Miner Res; 2003 Apr; 18(4):610-4. PubMed ID: 12674321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.